Sanofi Data Shows Vaccine Candidate Effective In Dengue Caused By 3 Virus Types

Sanofi:Pivotal PhaseIII JAKARTA Study Meets Primary Endpoint In Both Dose Groups

Sanofi Q1 Profit Drops On Generic Competition; Backs Full Year EPS View

Genzyme Announces Positive Results From TOPIC Trial For Aubagio

Sanofi Pasteur's Quadrivalent Influenza Vaccine Accepted For Review In Europe

Trade SNY now with

9/11/2012 12:25 AM ET

French drugmaker Sanofi's (SNY: Quote,SNYNF: Quote) vaccines division Sanofi Pasteur late Monday announced the online publication of clinical study results showing that its vaccine candidate protects against dengue fever caused by three dengue virus types.

The results of the world's first efficacy study confirm the safety profile of the dengue vaccine candidate, the firm said. The study results have been published in The Lancet.

Dengue is a mosquito-borne disease caused by four dengue virus serotypes. It is a threat to nearly 3 billion people, especially in some countries of Latin America and Asia.

The full analysis of vaccine efficacy against each serotype, reflecting real-life conditions, showed vaccine efficacy to be 61.2 percent against dengue virus type 1, 81.9 percent against type 3 and 90 percent against type 4.

One of the dengue virus types (serotype 2) eluded the vaccine. Sanofi said analyses are in progress to understand the lack of protection for serotype 2 in the particular epidemiological context of Thailand.

The study was conducted in 4,002 children aged 4 to 11 years, in partnership with the Mahidol University under the patronage of the Thai Ministry of Public Health.

Sanofi Pasteur's dengue vaccine candidate is a live, attenuated vaccine. The vaccination schedule is 3 doses given 6 months apart at 0, 6 and 12 months.

Dr. Scott Halstead, International Vaccine Institute, Seoul, Republic of Korea, said, ''The complexity of dengue virus infection has hampered vaccine research for decades. This is the first time in 50 years of dengue research that I have seen a vaccine that protected a large group of children from clinical disease caused by dengue viruses. Best yet, the vaccine met the highest safety expectations."

Large-scale phase III clinical studies of the dengue vaccine candidate are underway with 31,000 children and adolescents in 10 countries in Asia and Latin 2/3 America. These studies are expected to generate additional data in a broader population and in several epidemiological settings.

Sanofi closed in Paris on Monday lower by 0.65 percent at 65.72 euros on 2.01 million shares.

To receive FREE breaking news email alerts for Sanofi and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

More Breaking News

<<Previous 64 Articles

Editors Pick

Thailand Cuts 2013 GDP Outlook As Q1 Growth Slows More Than Expected

Thailand lowered its full-year growth outlook after weaker domestic demand and exports weighed on economic activity in the first three months of the year. Gross domestic product expanded 5.3 percent year-on-year in the first quarter of 2013 compared to an upwardly revised 19.1 percent growth in the fourth quarter of 2012, the National Economic and Social Development Board (NESDB) said Monday.

U.K. House Prices Hit Record High: Rightmove

The fifth consecutive monthly increase in the U.K. house prices amid limited supply took average asking prices to a record, a survey by Rightmove showed Monday. House prices hit a record GBP 249,841 in May, as new sellers raised their prices by 2.1 percent from the prior month. Prices were up by the same magniture in April.

Japan Upgrades Economic View Amid Export Recovery

The Japanese government on Monday upgraded its assessment of the economy for the first time in two months, as a weak yen helped revive the country's exports and factory output. "The Japanese economy is picking up slowly," the Cabinet Office said in its May monthly report. This was an upgrade from previous month's assessment when it said that economy was showing signs of picking up.